Actively Recruiting
Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-04-06
3200
Participants Needed
1
Research Sites
824 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: Some diseases cause chronic inflammation with intermittent flares in the body. These are called autoinflammatory diseases. They can cause fevers, rashes, ulcers, and other problems. Researchers want to learn more about the causes and effects of these diseases. They hope this will improve how the disease is managed in the future. Objectives: To understand the underlying immune dysregulation To identify the genetic cause To translate our findings into novel treatments that improve patients disease outcomes Eligibility: Patients with known NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's Disease, and with other yet undifferentiated autoinflammatory diseases. Unaffected relatives of participants with a known or undifferentiated autoinflammatory disease Healthy adult volunteers at least 18 years of age Design: Participants will be screened with blood sample and medical history. They may provide copies of their medical records. Enrolled participants will be evaluated at the NIH for 2-5 days. All participants will have a detailed medical history, physical exam, blood tests, and other evaluations depending on the extent of their autoinflammatory disease. Participants may also expect the following assessments: 1. Clinical tests that help assess organ damage and function such as hearing, vision, memory, and learning tests. 2. Imaging studies to characterize organ involvement of the inflammatory disease including: X-rays, CT scans, special MRIs, and bone scans. 3. Laboratory evaluations including clinical markers of disease activity, research samples for genetic studies, blood samples for cytokine/biomarker assessment, and gene expression profiling. 4. Questionnaires to assess disease activity and quality of life. 5. If indicated, other procedures may be administered that include: a lumbar puncture if CNS inflammation is suspected, a skin biopsy if skin inflammation is present, and/or gastrointestinal and pulmonary procedures if they are clinically indicated. Participants may return for a single follow-up visit or for long-term follow-up visits depending on their disease and willingness to return. Long-term follow-up may occur for up to 15 years on this protocol.
CONDITIONS
Official Title
Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be 2 to 99 years old for participants seen at NIH Clinical Center; newborn to 99 years old for remote participants.
- Willing to allow storage of biological samples for future research.
- Willing to allow genetic testing on collected samples.
- Have a primary care or other physician managing all health conditions.
- Have a known genetic mutation causing NOMID/CAPS, DIRA, CANDLE, SAVI, or NLRC4-MAS, or
- Have clinical signs consistent with IL-1 mediated autoinflammatory disease and evidence of systemic inflammation, or
- Have clinical signs consistent with IFN-mediated autoinflammatory disease and evidence of systemic inflammation, or
- Have clinical signs consistent with an undifferentiated autoinflammatory disease.
- Alternatively, previously enrolled in related NIAMS study 03-AR-0173.
- For unaffected relatives: be related by blood to an affected participant and not meet affected participant criteria.
- For healthy volunteers: be at least 18 years old, not related to affected participants, and not meet affected participant criteria.
- Able to provide informed consent.
You will not qualify if you...
- Conditions that may put the participant at undue risk or make them unsuitable for the study.
- Evidence of lymphoma, leukemia, or multiple myeloma unless associated with a known autoinflammatory disease and subsequent malignancy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
K
Katsiaryna Uss
CONTACT
R
Raphaela T Goldbach-Mansky, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here